Summary of Results
FAB Subtype . | Patient No. . | EpoR Analysis . | 3H-Thymidine Incorporation on Epo . | STAT5 Activation on Epo . | GATA-1 Activation on Epo . |
---|---|---|---|---|---|
RA | 1 | — | Low | Low pos/no | No |
2 | — | No | No | No | |
3 | Normal | — | — | — | |
RARS | 4 | Normal | — | — | — |
RAEB | 5 | Normal | — | — | — |
6 | — | No | No | No | |
7 | — | No | No | No | |
8 | Normal | No | No | No | |
9 | Normal | — | — | — | |
RAEB-t | 10 | — | No | No | No |
11 | — | No | Low pos | No | |
12 | Normal | — | — | — | |
13 | Normal | No | No | Low | |
14 | Normal | No | No | Low | |
15 | — | No | No | Low | |
CMML | 16 | Normal | No | Low pos/no | Low |
17 | — | No | No | No | |
18 | Normal | — | — | — | |
19 | — | Low | Low pos/no | Low | |
20 | — | No | No | No | |
21 | — | Low | No | Low |
FAB Subtype . | Patient No. . | EpoR Analysis . | 3H-Thymidine Incorporation on Epo . | STAT5 Activation on Epo . | GATA-1 Activation on Epo . |
---|---|---|---|---|---|
RA | 1 | — | Low | Low pos/no | No |
2 | — | No | No | No | |
3 | Normal | — | — | — | |
RARS | 4 | Normal | — | — | — |
RAEB | 5 | Normal | — | — | — |
6 | — | No | No | No | |
7 | — | No | No | No | |
8 | Normal | No | No | No | |
9 | Normal | — | — | — | |
RAEB-t | 10 | — | No | No | No |
11 | — | No | Low pos | No | |
12 | Normal | — | — | — | |
13 | Normal | No | No | Low | |
14 | Normal | No | No | Low | |
15 | — | No | No | Low | |
CMML | 16 | Normal | No | Low pos/no | Low |
17 | — | No | No | No | |
18 | Normal | — | — | — | |
19 | — | Low | Low pos/no | Low | |
20 | — | No | No | No | |
21 | — | Low | No | Low |